Raffaella Muraro

TL;DR: It is demonstrated in humans that RAGE overexpression is associated with enhanced inflammatory reaction and COX-2/mPGES-1 expression in diabetic plaque macrophages, and this effect may contribute to plaque destabilization by inducing culprit metalloproteinase expression.

TL;DR: It is demonstrated that one or more of the anti-TAG-72 CC MAbs may be more efficient than B72.3, or useful in combination with B72,3, toward the further study of human carcinoma cell population and the diagnostic and therapeutic procedures presently utilizing MAb B 72.3.

TL;DR: These studies provide a well-characterized repertoire of MAbs that are well suited for potential clinical trials involving the radiolocalization and possibly therapy of human colon carcinoma lesions, and provides the opportunity for testing the efficacy of cocktails of the COL MAbs toward these goals.

TL;DR: It is demonstrated that all six CC MAbs evaluated are superior to B72.3 in an in vivo tumor targeting model, using human colon carcinoma xenografts in athymic mice, in terms of both the percentage of the injected dose of radiolabeled MAb delivered per g of tumor and tumor:normal tissue ratios.

TL;DR: This study supports the hypothesis that simvastatin inhibits plaque RAGE expression by decreasing MPO-dependent AGE generation, which might contribute to plaque stabilization by inhibiting the biosynthesis of PGE2-dependent MMPs, responsible for plaque rupture.